Patents Issued in March 22, 2016
  • Patent number: 9289393
    Abstract: The invention provides a single stroke compression molding machine including: a die table having a die bore penetrating vertically; a slidable lower punch located below the die bore and having an upper end to be inserted to the die bore; a slidable upper punch located above the die bore to face the lower punch and having a lower end to be inserted to the die bore; and a dust collector configured to collect dust on an upper surface of the die table in a state where the lower end of the upper punch is located in the die bore.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: March 22, 2016
    Assignee: KIKUSUI SEISAKUSHO, LTD.
    Inventor: Tomohiro Kakitani
  • Patent number: 9289394
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: March 22, 2016
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 9289395
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: March 22, 2016
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Paul J. Davis, Shaker A. Mousa
  • Patent number: 9289396
    Abstract: The disclosure provides collagen-based constructs for use in drug delivery.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: March 22, 2016
    Assignee: Euclid Systems Corporation
    Inventors: Dale P. Devore, Bruce H. Dewoolfson, Eliot Lazar
  • Patent number: 9289397
    Abstract: The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: March 22, 2016
    Assignee: PURDUE PHARMA L.P.
    Inventor: Curtis Wright, IV
  • Patent number: 9289398
    Abstract: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: March 22, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Neil Almstead, Guangming Chen, Samit Hirawat, Peter Seongwoo Hwang, Gary M. Karp, Langdon Miller, Young-Choon Moon, Hongyu Ren, James J. Takasugi, Ellen M. Welch, Richard G. Wilde, Paul Kennedy
  • Patent number: 9289399
    Abstract: The invention concerns a pharmaceutical composition characterized in that it contains a combination of a parasympatholytic agent, a sympathomimetic agent and a local anaesthetic. Such a composition may be injected into the anterior chamber of the eye before a cataract operation or instilled on the eye before laser treatment.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: March 22, 2016
    Assignee: LABORATOIRES THEA
    Inventor: Walid Khatib
  • Patent number: 9289400
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: March 22, 2016
    Assignees: Drexel University, Rutgers, The State University of New Jersey
    Inventors: Sandhya Kortagere, Eldo V. Kuzhikandahil
  • Patent number: 9289401
    Abstract: A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 .mu.g hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 22, 2016
    Inventor: Darlene E. McCord
  • Patent number: 9289402
    Abstract: The present invention provides composites comprising at least one bioactive agent entrapped within a matrix of at least one metal; wherein said composite controllably releases at least one of said bioactive agent and metal or ion thereof, processes for the preparation of composites of the invention, compositions and products comprising composites of the invention and various uses thereof.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: March 22, 2016
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASSAH ACADEMIC COLLEGE
    Inventors: David Avnir, Rachel Ben-Knaz, Rami Pedahzur
  • Patent number: 9289403
    Abstract: The invention provides a method of reducing spasticity in a mammal involving administering modafinil or related compounds. The spasticity can be secondary to multiple sclerosis, spinal cord injury, stroke, brain injury, and other causes.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: March 22, 2016
    Assignee: The Board of Trustees of the University of Arizona
    Inventor: Edgar Garcia-Rill
  • Patent number: 9289404
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprises 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: March 22, 2016
    Assignees: HOUGH EAR INSTITUTE, OKLAHOMA MEDICAL RESEARCH FOUNDATION
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Patent number: 9289405
    Abstract: The invention relates to the use of compounds of general formula (I): CH3(—CH?CH)3—R??(I) wherein R is selected from CO—O—R? or CO—O(?), R? being selected from H, alkyl or alkenyl from C1 to C22, or sugars, and their pharmaceutically acceptable salts, preferably such as sodium, potassium, or lysine salts, each compound of general formula (I) being used as such or mixed with one or more of the others, as active ingredients in a pharmaceutical or cosmetic composition provided with antioxidant activity against free radicals.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: March 22, 2016
    Assignee: GIULIANI S.P.A
    Inventors: Giammaria Giuliani, Anna Benedusi
  • Patent number: 9289406
    Abstract: The present disclosure provides methods for treating hepatic encephalopathy (HE) and for optimizing and adjusting nitrogen scavenging drug dosage for subjects with HE.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 22, 2016
    Assignee: Horizon Therapeutics, Inc.
    Inventors: Bruce Scharschmidt, Masoud Mokhtarani
  • Patent number: 9289408
    Abstract: Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: March 22, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Lawrence A. Trissel, Yanping Zhang
  • Patent number: 9289409
    Abstract: Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: March 22, 2016
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: John Myers Zanella, Vanja M King, Christopher M Hobot, S Mark Cox, Danielle Biggs, Katara Shaw, William F McKay, Kathy L Remsen
  • Patent number: 9289410
    Abstract: The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: March 22, 2016
    Assignee: QBiotics Limited
    Inventors: Paul Warren Reddell, Victoria Anne Gordon
  • Patent number: 9289411
    Abstract: Provided is a novel anti-HCV agent including as an active ingredient a peroxide derivative represented by the general formula (I). In the general formula (I), C represents an alicyclic hydrocarbon ring group which may be substituted, n represents an integer of from 1 to 6, and R represents a hydrogen atom or a hydroxyalkyl group. The peroxide derivative exhibits potent anti-HCV activity by remarkably suppressing HCV-RNA replication.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: March 22, 2016
    Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Nobuyuki Kato, Masanori Ikeda, Yusuke Wataya, Hye-Sook Kim, Hiroyuki Doi
  • Patent number: 9289412
    Abstract: Disclosed herein are neuroprotective compounds. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of neurodegenerative conditions are provided.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: March 22, 2016
    Assignee: The Johns Hopkins University
    Inventors: Joseph P. Steiner, Avindra Nath, Norman Haughey
  • Patent number: 9289413
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 22, 2016
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 9289414
    Abstract: The methods and compositions disclosed herein relate to using carbazole, and derivatives thereof to modify a signaling activity such as epidermal growth factor receptor (EGFR) signalling, and angiogenesis activity, in a cell.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: March 22, 2016
    Inventor: Jack L. Arbiser
  • Patent number: 9289415
    Abstract: This disclosure provides agents, compositions and methods of treating cancer by inhibiting histone lysine specific demethylase 1 (LSD1) and/or and a histone lysine specific demethylase 2 (LSD2). Agents and compositions comprise statins and/or inhibitors of LSD1/2.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: March 22, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Yujiang Geno Shi, Christine Guo Lian
  • Patent number: 9289416
    Abstract: A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6?-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: March 22, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Nadja Gruening, Marc Schiller, Ashish Hemani, Chris Kirby, Ingo Friedrich, John Bothmer, Andreas Scholz
  • Patent number: 9289417
    Abstract: Methods for regulating the formation of a sulfilimine crosslink in a subject by administering a sulfilimine crosslink modulator are disclosed The sulfilimine modulator may inhibit or create a sulfilimine crosslink and maybe useful for treating a disease, such as cancer The sulfilimine crosslink may be between two or more peptides.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: March 22, 2016
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Billy G. Hudson, Roberto Vanacore, Gautam Bhave, Vadim Pedchenko
  • Patent number: 9289418
    Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 22, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Christopher Chang
  • Patent number: 9289419
    Abstract: The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: March 22, 2016
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Pradip Kumar Sasmal, Shahadat Ahmed, Ganesh Prabhu, Ashok Tehim, Vidyadhar Paradkar, Marahanakuli Prasanna Dattatreya, Nanjegowda Jagadeesh Mavinhalli
  • Patent number: 9289420
    Abstract: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: March 22, 2016
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M. B. Luhrs
  • Patent number: 9289421
    Abstract: The present disclosure provides methods and pharmaceutical compositions for reducing the serum level of immunoglobulin IgE in an animal or human subject. It has been found that reducing or inhibiting the activity of the cannabinoid receptor CB2 leads to an increase in IgE in serum levels. Conversely, activation of the CB2 receptor by an agonist results in a reduction in IgE serum levels. The compositions and methods of the disclosure, therefore, provide a means to reduce or eliminate symptoms of immune system-related conditions resulting from IgE generation, such as an allergy, hay fever, and the like.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: March 22, 2016
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Thomas W. Klein, Catherine Newton, Catherine Patterson, Marisela Agudelo
  • Patent number: 9289422
    Abstract: A method includes holding in a memory of a receiver, for each temperature in a range of temperatures, a respective first parameter indicative of a frequency error of a crystal oscillator in the receiver at the temperature, and a respective second parameter indicative of an uncertainty of the first parameter. An operating temperature of the crystal oscillator is measured. One or more frequencies, for initial acquisition of signals from a transmitter, are selected based on the first and second parameters corresponding to the measured operating temperature. The receiver is tuned to receive the signals from the transmitter on at least one of the selected frequencies.
    Type: Grant
    Filed: March 18, 2012
    Date of Patent: March 22, 2016
    Assignee: MARVELL WORLD TRADE LTD.
    Inventors: David Ben-Eli, Alexander Zaslavsky
  • Patent number: 9289423
    Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 22, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Mary Maral Mouradian, Steven Braithwaite, Michael Voronkov
  • Patent number: 9289425
    Abstract: Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 22, 2016
    Assignee: AntiOp, Inc.
    Inventors: Joseph Wyse, Michael Paul DeHart
  • Patent number: 9289426
    Abstract: The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: March 22, 2016
    Assignee: UNIVERSITY OF PENNSYLVANIA
    Inventors: Ronald J Buckanovich, George Coukos, Andrea Facciabene
  • Patent number: 9289427
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: March 22, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz-Hermann Bokel, Frank Stieber, Cristina Donini
  • Patent number: 9289428
    Abstract: The present embodiments provide for sustained release formulations of antioxidants that are useful in treating afflictions of the eye and tumors.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: March 22, 2016
    Assignee: RAMSCOR, INC.
    Inventors: Vernon G. Wong, Louis L. Wood, Carol Wood
  • Patent number: 9289429
    Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: March 22, 2016
    Assignee: Ardelyx, Inc.
    Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
  • Patent number: 9289430
    Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: March 22, 2016
    Assignee: Ardelyx, Inc.
    Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
  • Patent number: 9289431
    Abstract: An antitumor effect potentiator for potentiating one or more other antitumor agents, comprising, as an active ingredient, an imidazooxazine compound represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, B, C, and D represent C—R1a, C—R1b, C—R1c, and C—R1d, respectively, or one or two of A, B, C, and D represent an N atom; at least two of R1a, R1b, R1c, and R1d represent hydrogen, and the other(s) represent(s) halogen; cyano; C1-6 alkyl that may have hydroxyl group(s) as substituent(s); C1-6 alkoxy; carbonyl having, as a substituent, hydroxyl, amino, optionally substituted mono- or di-(C1-6 alkyl)amino, or mono- or di-(C1-6 alkoxy)amino; or an unsaturated heterocyclic group; R2 represents phenyl, pyridyl, or thienyl; R3 represents hydrogen, methyl, ethyl, or cyclopropyl; and R4 represents hydrogen or hydroxy.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: March 22, 2016
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Koji Ichikawa, Megumu Okada
  • Patent number: 9289432
    Abstract: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: March 22, 2016
    Assignee: HANANJA EHF and UNIVERSITY OF ICELAND
    Inventor: Sveinbjorn Gizurarson
  • Patent number: 9289433
    Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: March 22, 2016
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Irina Lavelin, Varda Rotter, Moshe Oren, Ami Navon, Zvi Kam, Benjamin Geiger
  • Patent number: 9289434
    Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 22, 2016
    Assignees: Aeolus Sciences, Inc., National Jewish Health, Duke University
    Inventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polivina Jolicia F. Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle
  • Patent number: 9289435
    Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 22, 2016
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Kumble Sandeep Prabhu, Robert Frank Paulson, Shailaja Hegde, Naveen Kaushal, Ujjawal Hitendra Gandhi
  • Patent number: 9289436
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: March 22, 2016
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Patent number: 9289437
    Abstract: The present invention relates to a method for the preparation of a controlled release system and especially to a method for entrapment of compounds in polymer carriers for controlled release of active ingredients, preferably bioactive ingredients, such as drugs. This method results in a system for controlled release of active ingredients and especially for controlled drug delivery. In accordance with the present invention, the term “controlled release” encompasses all kinds of controlled release, including slow release, sustained and delayed release. Particularly, the present invention results in active ingredients, entrapped in or otherwise incorporated in or coupled to polymer carriers or polymeric devices, such as micelles, nanoparticles, microspheres and other types of polymer devices for controlled release; the active ingredients are covalently bonded to the polymer carriers or polymeric devices.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: March 22, 2016
    Assignee: CRISTAL DELIVERY B.V.
    Inventors: Cristianne Johanna Ferdinand Rijcken, Wilhelmus Everhardus Hennink, Cornelis Franciscus Van Nostrum
  • Patent number: 9289438
    Abstract: A method of treating high grade temperature using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9289439
    Abstract: A method of reducing hepatocellular damage in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9289440
    Abstract: A method of treating myocardial infarction in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: March 22, 2016
    Assignee: THEAPRIN PHARMACEUTICALS INC.
    Inventors: Harry G. Brittain, Philip V. Felice
  • Patent number: 9289441
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: March 22, 2016
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Jaro I. Karppinen
  • Patent number: 9289442
    Abstract: Provided herein are anhydrous compositions that include at least one viscosity increasing agent, at least one organic solvent and at least one humectant. Such compositions may also include at least one active pharmaceutical ingredient (API) and/or at least one water repellant. Related compositions, methods and kits are also provided.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 22, 2016
    Assignee: Novan, Inc.
    Inventors: Ryan Doxey, Nathan Stasko
  • Patent number: 9289443
    Abstract: A pharmaceutical composition for preventing or treating hepatitis C is provided, including oleanolic acid derivatives as an active ingredient and a pharmaceutically acceptable carrier. A method for preventing or treating hepatitis C in a subject in need thereof is also provided by administering the subject the pharmaceutical composition given above.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: March 22, 2016
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Lain-Tze Lee, Shau-Feng Chang, Zong-Keng Kuo, Hui-Ping Tsai
  • Patent number: 9289444
    Abstract: This invention relates to a composition for promoting hematopoiesis and for treating, preventing or alleviating cytopenia or bone marrow failure comprising quercetin 3-O-?-(2?-galloyl)-rhamnopyranoside (QGR) as active ingredient.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: March 22, 2016
    Assignee: Chungbuk National University Industry Academic Cooperation Foundation
    Inventors: Byeong Woo Ahn, Young Soo Kim, Heon Sang Jeong, Sang-Kyung Shin, Tae-Wang Kim, So-Young Youm